Creating Brighter Horizons for Patients

LumiThera is a global ophthalmic medical device company offering a comprehensive portfolio for detecting, treating, and monitoring retinal diseases, specifically dry age-related macular degeneration (AMD). Our mission is to provide light-based innovations that help preserve and improve patients’ quality of life.

Harnessing the Power of Light™
to Preserve and Improve Vision

LumiThera is developing products to improve visual function, slow or stop the progression of debilitating retinal diseases, and prevent vision loss. Through our commitment to innovation and rigorous clinical programs, LumiThera continues to push the boundaries of vision science.

Leading Photobiomodulation Innovation

LumiThera is the leader in ophthalmic photobiomodulation (PBM) with the Valeda® Light Delivery System. Valeda is the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD) to improve vision. Valeda demonstrates improvements in clinical and anatomical outcomes, which support a disease-modifying benefit for patients with dry age-related macular degeneration (AMD). In addition to clinical benefits, Valeda has a proven and well-established safety profile.

U.S. Indications for Use

The Valeda Light Delivery System is intended to provide improved visual acuity in patients with best-corrected visual acuity of 20/32 through 20/70 and who have dry age-related macular degeneration (AMD) characterized by:

The presence of at least 3 medium drusen (> 63 μm and ≤ 125 μm in diameter), or large drusen (> 125 μm in diameter), or non-central geographic atrophy, AND The absence of neovascular maculopathy or central-involving geographic atrophy After about two years, the Valeda Light Delivery System treatment provides improved mean visual acuity of approximately one line of visual acuity (ETDRS) compared to those not receiving the treatment.

Indications for Use outside the U.S.*

The indicated use is for treatment of ocular damage and disease using photobiomodulation, including inhibition of inflammatory mediators, edema or drusen deposition, improvement of wound healing following ocular trauma or surgery, and increase in visual acuity and contrast sensitivity in patients with degenerative diseases such as dry age-related macular degeneration.

*Indications for use determined by region. Contact LumiThera for more information.

As a precaution, patients have not been tested and should not be treated with Valeda if they have any known photosensitivity to yellow light, red light, or near-infrared radiation (NIR), or if they have a history of light-activated central nervous system disorders (e.g., epilepsy, migraine). In addition, patients should not receive treatment within 30 days of using photosensitizing agents (e.g., topicals, injectables) that are affected by 590, 660, and/or 850 nm light before consulting with their physician.

Refer to the Valeda User Manual for full Important Safety Information.